Project Details
Description
PROJECT NARRATIVE
About 50% of patients prescribed statins do not obtain critical benefits in lowering low-density lipoprotein
cholesterol, preventing atherosclerotic cardiovascular disease, and reducing all-cause mortality because they
discontinue use within 1 year of treatment initiation largely due to statin-associated symptoms. Statin
discontinuation has been identified as a major public-health concern due to increased morbidity, mortality, and
healthcare costs associated with atherosclerotic cardiovascular disease. The proposed study will produce a
personalized (“precision”)-medicine tool using big data to empower physicians to make proactive clinical
decisions for prescribing statins that will maximize LDL reduction and minimize statin discontinuation and
statin-associated symptoms.
Status | Finished |
---|---|
Effective start/end date | 2/15/19 → 1/31/23 |
Funding
- National Heart, Lung, and Blood Institute: $662,105.00
- National Heart, Lung, and Blood Institute: $758,900.00
- National Heart, Lung, and Blood Institute: $782,736.00
- National Heart, Lung, and Blood Institute: $671,656.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.